Abstract
Leukemia is the most common malignancy in childhood. There have been major advances in our understanding of the biology of leukemia. Better supportive care and increased treatment intensity have led to significant improvements in the outcome of children with acute lymphoblastic and myelogeneous leukemias. Hematopoietic stem cell transplantation is used as treatment for patients in whom conventional-dose chemotherapy fails to induce a response. It is also used for patients in whom high-risk features are noted during first complete remission.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Suggested Readings
Arceci RJ. Progress and controversies in the treatment of pediatric acute myelogenous leukemia. Curr Opin Hematol 2002;9:353–360.
Chessels JM, Veys P, Kempski H, et al. Long-term follow-up of relapsed childhood acute lymphoblastic leukemia. Br J Haematol 2003;123:396–405.
Gaynon PS, Trigg ME, Heerema NA, et al. Children’s Cancer Group trials in childhood acute lymphoblastic leukemia: 1993–1995. Leukemia 2000;14:2223–2233.
Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001;97:631–637.
Grimwade D, Walker H, Oliver F, et al. On behalf of The Medical Research Council Adult and Children’s Leukemia Working Parties The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998;92:2322–2333.
Hann I, Stevens R, Goldstone A, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council’s 10th AML trial (MRC AML 10). Blood 1997;89:2311–2318.
Howard SC, Gajjar AJ, Chang C, et al. Risk factors for traumatic and bloody lumbar puncture in children with acute lymphoblastic leukemia. JAMA 2002;288:2001–2007.
Issa JP, Garcia-Manero G, Giles FJ, et al. Phase I study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004;103:1635–1640.
Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004;103:784–789.
Kottaridis PD, Gale RE, Frew MR, et al. The presence of a FLT-3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk groupand response to the first cycle of chemotherapy: analysis of 854 patients from United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001;98:1752–1759.
Lazo G, Kantarjian H, Estey E, et al. Use of arsenic trioxide (AO3) in the treatment of patients with acute promyelocytic leukemia. Cancer 2003;97:2218–2224.
Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 1998;338:1663–1671.
Neudorf S, Sanders J, Kobrinsky N, et al. Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrated a role for graft-versus-leukemia in the maintenance of disease-free survival. Blood 2004;103:3655–3661.
Patte C. Treatment of mature B-ALL and high grade B-NHL in children. Best Pract Res Clin Haematol 2003;15:695–711.
Pui CH, Relling RV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004;350:1535–1548.
Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munich trial NHL-BFM 90. Blood 1999;94:3294–3306.
Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004;103:4396–4407.
Uderzo C. Indications and role of allogeneic bone marrow transplantation in childhood very high risk acute lymphoblastic leukemia in first complete remission. Haematologica 2000;85:9–11.
Uderzo C, Dini G, Locatelli F, et al. Treatment of childhood acute lymphoblastic leukemia after first relapse: curative strategies. Haematologica 2000;85:47–53.
Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children’s Cancer Group. Blood 1996;87:4979–4989.
Woods WG, Neudorf S, Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001; 97:56–62.
Wossman W, Schrappe M, Meyer U, et al. Incidence of tumor lysis syndrome in children with advanced stage Burkitts lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol 2003;82:160–165.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
Rytting, M.E., Choroszy, M.S., Petropoulos, D., Chan, K.W. (2005). Acute Leukemia. In: Chan, K.W., Raney, R.B. (eds) Pediatric Oncology. M.D. Anderson Cancer Care Series, vol 4. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-24472-3_1
Download citation
DOI: https://doi.org/10.1007/978-0-387-24472-3_1
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-24470-9
Online ISBN: 978-0-387-24472-3
eBook Packages: MedicineMedicine (R0)